Sleep Cycle Framtida tillväxt
Future kriterier kontrolleras 4/6
Sleep Cycle förväntas öka intäkter och intäkter med 13.3% respektive 10% per år. EPS förväntas falla med 19.7% per år. Avkastningen på eget kapital förväntas bli 28.2% om 3 år.
Viktig information
13.3%
Tillväxttakt i vinsten
-19.71%
Tillväxttakt för EPS
| Software vinsttillväxt | 35.2% |
| Intäkternas tillväxttakt | 10.0% |
| Framtida avkastning på eget kapital | 28.17% |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 30 Apr 2026 |
Senaste uppdateringarna om framtida tillväxt
Analysartikel • May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00
It's been a sad week for Sleep Cycle AB (publ) ( STO:SLEEP ), who've watched their investment drop 17% to kr15.34 in...Analysartikel • Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts
As you might know, Sleep Cycle AB (publ) ( STO:SLEEP ) last week released its latest first-quarter, and things did not...Recent updates
Analysuppdatering • May 07
SLEEP: Respiratory Research And Sleep Apnea Solution Will Drive Long Term Upside
Analysts have trimmed their price target on Sleep Cycle from SEK30.75 to about SEK28.83, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping the app included in exclusive offerings for Premium, Metal and Ultra customers and giving access to a large, premium user base for its sleep optimization features (Client Announcements).Analysartikel • May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00
It's been a sad week for Sleep Cycle AB (publ) ( STO:SLEEP ), who've watched their investment drop 17% to kr15.34 in...
Analysuppdatering • Apr 21
SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery
Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).Analysuppdatering • Apr 04
SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential
Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.Analysuppdatering • Mar 21
SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside
Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.Analysuppdatering • Mar 06
SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside
Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.Analysuppdatering • Feb 19
SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside
Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.Analysartikel • Feb 09
These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts
One thing we could say about the analysts on Sleep Cycle AB (publ) ( STO:SLEEP ) - they aren't optimistic, having just...Analysartikel • Feb 07
Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53
Sleep Cycle AB (publ) ( STO:SLEEP ) is reducing its dividend from last year's comparable payment to SEK0.53 on the 20th...
Analysuppdatering • Feb 04
SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play
Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).Analysuppdatering • Jan 21
SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside
Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.Analysuppdatering • Jan 06
SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside
Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).Analysartikel • Jan 04
There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings
Sleep Cycle AB (publ)'s ( STO:SLEEP ) price-to-earnings (or "P/E") ratio of 9.2x might make it look like a strong buy...Analysuppdatering • Dec 15
SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential
Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.Analysartikel • Sep 09
Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%
Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a really impressive month, gaining 30% after a shaky period...Analysartikel • Aug 27
Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.
The main catalyst behind Sleep Cycle’s upside potential, why JB Hi-Fi might have lost its point of difference, and the bear, base and bull case for Figma.
Analysuppdatering • Aug 23
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.Analysuppdatering • Aug 22
Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities
Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.Analysartikel • Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts
As you might know, Sleep Cycle AB (publ) ( STO:SLEEP ) last week released its latest first-quarter, and things did not...Analysartikel • Apr 29
The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%
Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a horrible month, losing 34% after a relatively good period...Analysartikel • Apr 08
Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00
Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...
Ny analys • Mar 18
Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships
Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.Analysartikel • Mar 06
Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's
Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...Analysartikel • Feb 10
Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year
Sleep Cycle AB (publ) ( STO:SLEEP ) will increase its dividend from last year's comparable payment on the 15th of April...Ny analys • Feb 10
Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model
Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device forPrognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 298 | 47 | 46 | 67 | 2 |
| 12/31/2027 | 258 | 38 | 48 | 64 | 2 |
| 12/31/2026 | 218 | 10 | -29 | 16 | 2 |
| 3/31/2026 | 236 | 45 | 22 | 43 | N/A |
| 12/31/2025 | 248 | 53 | 40 | 53 | N/A |
| 9/30/2025 | 257 | 59 | 49 | 59 | N/A |
| 6/30/2025 | 261 | 62 | 56 | 66 | N/A |
| 3/31/2025 | 263 | 65 | 55 | 62 | N/A |
| 12/31/2024 | 262 | 63 | 60 | 64 | N/A |
| 9/30/2024 | 256 | 56 | 60 | 63 | N/A |
| 6/30/2024 | 251 | 55 | 64 | 66 | N/A |
| 3/31/2024 | 243 | 49 | 65 | 69 | N/A |
| 12/31/2023 | 236 | 46 | 46 | 53 | N/A |
| 9/30/2023 | 229 | 39 | 40 | 50 | N/A |
| 6/30/2023 | 224 | 33 | 31 | 41 | N/A |
| 3/31/2023 | 218 | 33 | 27 | 37 | N/A |
| 12/31/2022 | 212 | 34 | 54 | 62 | N/A |
| 9/30/2022 | 206 | 37 | 64 | 70 | N/A |
| 6/30/2022 | 199 | 34 | 64 | 71 | N/A |
| 3/31/2022 | 191 | 14 | 49 | 55 | N/A |
| 12/31/2021 | 183 | 8 | 14 | 20 | N/A |
| 9/30/2021 | 177 | 6 | 8 | 13 | N/A |
| 6/30/2021 | 168 | 12 | 17 | 19 | N/A |
| 3/31/2021 | 163 | 33 | 35 | 36 | N/A |
| 12/31/2020 | 159 | 44 | 46 | 46 | N/A |
| 12/31/2019 | 123 | 42 | N/A | 48 | N/A |
| 12/31/2018 | 93 | 27 | N/A | 53 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: SLEEP s prognostiserade vinsttillväxt ( 13.3% per år) är över sparkvoten ( 2% ).
Resultat vs marknad: SLEEP s intäkter ( 13.3% per år) förväntas växa snabbare än marknaden för Swedish ( 8.9% per år).
Höga tillväxtresultat: SLEEP s intäkter förväntas växa, men inte avsevärt.
Intäkt vs marknad: SLEEP s intäkter ( 10% per år) förväntas växa snabbare än Swedish marknaden ( 0.1% per år).
Hög tillväxtintäkter: SLEEP s intäkter ( 10% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: SLEEP s avkastning på eget kapital förväntas bli hög om 3 år ( 28.2 %)
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/08 00:54 |
| Aktiekurs vid dagens slut | 2026/05/08 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Sleep Cycle AB (publ) bevakas av 4 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Oscar Erixon | Carnegie Investment Bank AB |
| Erik Granström | DNB Carnegie |
| Rikard Engberg | DNB Carnegie Commissioned Research |